PDCD1 and neoplasm: In 2020, Li et al. identified a specific inhibitor of ALKBH5, named ALK-04, which decreases the infiltration of Treg cells and MDSCs and inhibits tumor growth by enhancing the efficacy of anti-PD-1 therapy (Fig. 3) [88].